Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024)
Tango Therapeutics (TNGX) posted quarterly Non Operating Investment Income of -$443000.0 for Q1 2024, down 129.45% year-over-year from $1.5 million in Q2 2023, and down 151.1% quarter-over-quarter from $867000.0 in Q4 2023.
Powered by 
Analysis
Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024) Analysis & Trends
Tango Therapeutics' Non Operating Investment Income history runs 5 years deep, the most recent figure standing at -$443000.0 for Q1 2024.
- In Q1 2024, Non Operating Investment Income fell 129.45% year-over-year to -$443000.0; the TTM figure through Mar 2024 stood at $1.9 million (up 60.79% YoY), while the FY2025 annual figure was -$112000.0, down 174.67% from the prior year.
- Non Operating Investment Income for Q1 2024 stood at -$443000.0, down from $867000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $1.5 million in Q1 2023, with the low at -$2.6 million in Q1 2022.
- The 5-year median for Non Operating Investment Income is -$9000.0 (2020), against an average of -$17866.7.
- The sharpest annual moves came in 2022 and 2023: Non Operating Investment Income sank 17733.33% in 2022, then jumped 264.24% in 2023.
- Tango Therapeutics' Non Operating Investment Income stood at -$9000.0 in 2020, then tumbled by 8288.89% to -$755000.0 in 2021, then soared by 252.45% to $1.2 million in 2022, then slipped by 24.67% to $867000.0 in 2023, then plunged by 151.1% to -$443000.0 in 2024.
- Business Quant data shows TNGX's Non Operating Investment Income at -$443000.0 in Q1 2024, $867000.0 in Q4 2023, and $836000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Tango Therapeutics | 3.38 Bn | 2.36 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -443,000.00 |
| Dec 31, 2023 | 867,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Jun 30, 2023 | 684,000.00 |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | -509,000.00 |
| Jun 30, 2022 | -937,000.00 |
| Mar 31, 2022 | -2.65 Mn |
| Dec 31, 2021 | -755,000.00 |
| Sep 30, 2021 | -12,000.00 |
| Jun 30, 2021 | -30,000.00 |
| Mar 31, 2021 | 15,000.00 |
| Dec 31, 2020 | -9,000.00 |
| Sep 30, 2020 | 15,000.00 |